← Back to Search

Contrast-Enhanced Imaging for Liver Cancer (ACRIN6690 Trial)

N/A
Waitlist Available
Led By Christoph Wald, MD, PhD
Research Sponsored by American College of Radiology Imaging Network
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is looking at how well contrast-enhanced CT and MRI scans can detect and stage liver cancer in patients with chronic liver disease.

Eligible Conditions
  • Hepatocellular Carcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Waitlisted with HCC-Exception PointsExperimental Treatment3 Interventions
Participants undergo CT and MRI every 90 days for the trial with iodinated contrast dye and motexafin gadolinium, during liver transplant wait listing. Possible Eovist-enhanced MRI substudy participation
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Motexafin gadolinium
Not yet FDA approved

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,907 Previous Clinical Trials
41,011,704 Total Patients Enrolled
43 Trials studying Hepatocellular Carcinoma
5,595 Patients Enrolled for Hepatocellular Carcinoma
American College of Radiology Imaging NetworkLead Sponsor
39 Previous Clinical Trials
465,520 Total Patients Enrolled
Christoph Wald, MD, PhDPrincipal InvestigatorLahey Clinic Medical Center - Burlington

Media Library

iodinated contrast dye Clinical Trial Eligibility Overview. Trial Name: NCT01082224 — N/A
Hepatocellular Carcinoma Research Study Groups: Waitlisted with HCC-Exception Points
Hepatocellular Carcinoma Clinical Trial 2023: iodinated contrast dye Highlights & Side Effects. Trial Name: NCT01082224 — N/A
iodinated contrast dye 2023 Treatment Timeline for Medical Study. Trial Name: NCT01082224 — N/A
~29 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top